Titan Pharmaceuticals Correlations
TTNP Stock | USD 3.98 0.06 1.53% |
The correlation of Titan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Titan Pharmaceuticals Correlation With Market
Average diversification
The correlation between Titan Pharmaceuticals and DJI is 0.1 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Titan Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Titan |
Moving against Titan Stock
0.67 | NAMSW | NewAmsterdam Pharma Trending | PairCorr |
0.59 | XFOR | X4 Pharmaceuticals | PairCorr |
0.46 | HLVX | Hillevax | PairCorr |
0.39 | ILMN | Illumina Sell-off Trend | PairCorr |
0.36 | PFE | Pfizer Inc | PairCorr |
0.35 | TMO | Thermo Fisher Scientific | PairCorr |
0.57 | CGTX | Cognition Therapeutics | PairCorr |
0.41 | BNTC | Benitec Biopharma Upward Rally | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Titan Stock performing well and Titan Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Titan Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
FWBI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
SLRX | 8.20 | 0.69 | 0.08 | 0.20 | 7.30 | 15.57 | 161.82 | |||
SABS | 5.93 | (0.23) | 0.00 | 3.48 | 0.00 | 13.14 | 101.06 | |||
VCNX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
GOVX | 3.28 | (0.80) | 0.00 | (5.45) | 0.00 | 6.64 | 24.16 | |||
SNTI | 12.72 | 3.98 | 0.47 | (2.18) | 6.86 | 12.86 | 391.56 | |||
ZIVO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
CVKD | 4.40 | 0.63 | 0.12 | 1.04 | 4.80 | 11.59 | 25.08 | |||
FHTX | 3.76 | (0.54) | 0.00 | (0.26) | 0.00 | 9.05 | 23.64 |
Titan Pharmaceuticals Corporate Management
Brian Crowley | Senior Administration | Profile | |
Joe Schrei | Executive Operations | Profile | |
Weei Chay | Chief Officer | Profile | |
Marc MD | Ex Director | Profile | |
David Lazar | Principal Officer | Profile |